MGRX Mangoceuticals: רווח למניה ב-12 החודשים האחרונים

Mangoceuticals, Inc. (MGRX) efficiency is based on ESG standards and the digitalization of medicine, which eliminates paper documentation. Analyzing the chart on GURU.Markets, we find that the relative EPS YoY TTM growth rate is recorded at 63.10. The company is developing a private men's wellness environment with personalized medications, yet it faces risks due to a heavy dependence of profits on the cost of acquiring traffic from social networks.

The stable cash flow from Mangoceuticals, Inc. (MGRX) telemedicine segment is offset by aggressive marketing expenses, making the net earnings per share trend a critical efficiency marker. This measurement of annual EPS TTM growth compares the current rolling yield with the previous year, allowing investors to filter out operational noise and assess whether the business's digital momentum is translating into real growth in shareholder value.